Skip to main content

Advertisement

SpringerLink
Log in

Endocrine therapy in obese patients with primary breast cancer: another piece of evidence in an unfinished puzzle

  • Clinical trial
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Obesity, defined as a body mass index (BMI) ≥30 is an independent risk factor in breast cancer and is correlated with shorter survival and enhanced recurrence rates. The present subgroup analysis of the German BRENDA-cohort aimed to investigate the correlation between BMI, recurrence-free survival (RFS) and adjuvant endocrine therapy. In this subgroup analysis, 4,636 patients were retrospectively examined using multivariate analyses. Overall 3,759 (81.1%) patients had a BMI <30 (non-obese) and 877 (18.9%) a BMI ≥30 (obese). In the group of all 3,896 (84.0%) patients with hormone-receptor-positive (HR+) breast carcinomas a significant reduction in RFS was demonstrated for those who were obese (P = 0.002; HR = 1.45 (95% CI: 1.15–1.83)), also after adjustment for Nottingham Prognostic Index (NPI) (P = 0.028; HR = 1.30 (95% CI: 1.03–1.65)). In hormone-receptor-negative (HR−) patients BMI had no influence on RFS (P = 0.380; HR = 1.20 (95% CI: 0.80–1.81)). Considering menopausal status, a significantly shorter RFS was seen in postmenopausal obese than in non-obese patients (P < 0.001; HR = 1.61 (95% CI: 1.24–2.09)), whereas the premenopausal patient group only showed a trend towards a shorter RFS (P = 0.202; HR = 1.44 (95% CI: 0.82–2.53)). The group of HR+ postmenopausal patients with normal or intermediate weight showed a non-significant statistical trend towards a survival benefit for aromatase inhibitors (AI) compared to tamoxifen (RFS: P = 0.486; HR = 1.29 (95% CI: 0.63–2.62), while obese patients tended to benefit more from tamoxifen (RFS: P = 0.289; HR = 0.65 (95% CI: 0.29–1.45)). In accordance with recently published results we demonstrated a negative effect of a high BMI on outcome in primary breast cancer. Furthermore the efficacy of AI seems dependent on BMI in contrast to tamoxifen. Prospective studies to optimise the therapy of obese breast cancer patients are urgently needed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Morimoto LM, White E, Chen Z, Chlebowski RT, Hays J, Kuller L, Lopez AM, Manson J, Margolis KL, Muti PC, Stefanick ML, McTiernan A (2002) Obesity, body size, and risk of postmenopausal breast cancer: the Women’s Health Initiative (United States). Cancer Cause Control 13(8):741–751

    Article  Google Scholar 

  2. Reeves GK, Pirie K, Beral V, Green J, Spencer E, Bull D, Million Women Study Collaboration (2007) Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. Br Med J 335(7630):1134

    Article  Google Scholar 

  3. Loi S, Milne RL, Friedlander ML, McCredie MR, Giles GG, Hopper JL, Phillips KA (2005) Obesity and outcomes in premenopausal and postmenopausal breast cancer. Cancer Epidemiol Biomark 14(7):1686–1691

    Article  Google Scholar 

  4. Protani M, Coory M, Martin JH (2010) Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. Breast Cancer Res Treat 123:627–635

    Article  PubMed  Google Scholar 

  5. Dignam JJ, Wieand K, Johnson KA, Fisher B, Xu L, Mamounas EP (2003) Obesity, tamoxifen use, and outcomes in women with estrogen receptor-positive early-stage breast cancer. J Natl Cancer Inst 95(19):1467–1476

    Article  PubMed  CAS  Google Scholar 

  6. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ (2003) Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348(17):1625–1638

    Article  PubMed  Google Scholar 

  7. Whiteman MK, Hillis SD, Curtis KM, McDonald JA, Wingo PA, Marchbanks PA (2005) Body mass and mortality after breast cancer diagnosis. Cancer Epidemiol Biomark 14(8):2009–2014

    Article  Google Scholar 

  8. Majed B, Moreau T, Senouci K, Salmon RJ, Fourquet A, Asselain B (2008) Is obesity an independent prognosis factor in woman breast cancer? Breast Cancer Res Treat 111(2):329–342

    Article  PubMed  Google Scholar 

  9. Petrelli JM, Calle EE, Rodriguez C, Thun MJ (2002) Body mass index, height, and postmenopausal breast cancer mortality in a prospective cohort of US women. Cancer Cause Control 13(4):325–332

    Article  Google Scholar 

  10. Ewertz M, Jensen MB, Gunnarsdóttir KÁ, Højris I, Jakobsen EH, Nielsen D, Stenbygaard LE, Tange UB, Cold S (2011) Effect of obesity on prognosis after early-stage breast cancer. J Clin Oncol 29(1):25–31

    Article  PubMed  Google Scholar 

  11. WHO/Europe (2001) Obesity. http://www.euro.who.int/en/what-we-do/health-topics/noncommunicable-diseases/obesity. Accessed 27 May 2011

  12. Sestak I, Distler W, Forbes JF, Dowsett M, Howell A, Cuzick J (2010) Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial. J Clin Oncol 28(21):3411–3415

    Article  PubMed  CAS  Google Scholar 

  13. Pfeiler G, Stöger H, Fesl C, Singer C, Seifert M, Jakesz R, Dubsky P, Samonigg H, Greil R, Menzel C, Heck D, Gnant M on behalf of the ABCSG (2010) Impact of body mass index (BMI) on the efficacy of endocrine therapy in postmenopausal breast cancer patients—an analysis of the ABCSG 6 and 6a trial. http://www.abstracts2view.com/sabcs10/viewp.php?nu=PD09-05

  14. Pfeiler G, Königsberg R, Fesl C, Mlineritsch B, Stoeger H, Singer CF, Pöstlberger S, Steger GG, Seifert M, Dubsky P, Taucher S, Samonigg H, Bjelic-Radisic V, Greil R, Marth C, Gnant M (2011) Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial. J Clin Oncol 29:2653–2659

    Google Scholar 

  15. Goodwin PJ, Pritchard KI (2010) Obesity and hormone therapy in breast cancer: an unfinished puzzle. J Clin Oncol 28(21):3405–3407

    Article  PubMed  CAS  Google Scholar 

  16. Wöckel A, Varga D, Atassi Z, Kurzeder C, Wolters R, Wischnewsky M, Wulff C, Kreienberg R (2010) Impact of guideline conformity on breast cancer therapy: results of a 13-year retrospective cohort study. Onkologie 33(1–2):21–28

    PubMed  Google Scholar 

  17. Hancke K, Denkinger MD, König J, Kurzeder C, Wöckel A, Herr D, Blettner M, Kreienberg R (2010) Standard treatment of female patients with breast cancer decreases substantially for women aged 70 years and older: a German clinical cohort study. Ann Oncol 21(4):748–753

    Article  PubMed  CAS  Google Scholar 

  18. Wöckel A, Kurzeder C, Geyer V, Novopashenny I, Wolters R, Wischnewsky M, Kreienberg R, Varga D (2010) Effects of guideline adherence in primary breast cancer—a 5-year multi-center cohort study of 3976 patients. Breast 19(2):120–127

    Article  PubMed  Google Scholar 

  19. Regierer AC, Wolters R, Kurzeder C, Wöckel A, Novopashenny I, Possinger K, Wischnewsky MB, Kreienberg R (2011) High estrogen receptor expression in early breast cancer: chemotherapy needed to improve RFS? Breast Cancer Res Treat. doi:10.1007/s1054901013349

  20. Varga D, Wischnewsky M, Atassi Z, Wolters R, Geyer V, Strunz K, Kreienberg R, Woeckel A (2010) Does guideline-adherent therapy improve the outcome for early-onset breast cancer patients? Oncology 78(3–4):189–195

    Article  PubMed  Google Scholar 

  21. Maehle BO, Tretli S, Skjaerven R, Thorsen T (2001) Premorbid body weight and its relation to primary tumour diameter in breast cancer patients: its dependence on estrogen and progesterone receptor status. Breast Cancer Res Treat 68:159–169

    Article  PubMed  CAS  Google Scholar 

  22. Berclaz G, Li S, Price KN, Coates AS, Castiglinone-Gertsch M, Rudenstam CM, Holmberg SB, Lindtner J, Erien D, Collins J, Snyder R, Thürlimann B, Fey MF, Mendiola C, Werner ID, Simoncini E, Crivellari D, Gelber RD, Goldhirsch A, International Breast Cancer Study Group (2004) Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience. Ann Oncol 15:875–884

    Article  PubMed  CAS  Google Scholar 

  23. Cleveland RJ, Eng SM, Abrahamson PE, Britton JA, Teitelbaum SL, Neugut AI, Gammon MD (2007) Weight gain prior to diagnosis and survival from breast cancer. Cancer Epidemiol Biomark Prev 16:1803–1811

    Article  Google Scholar 

  24. Feigelson HS, Patel AV, Teras LR, Gansler TS, Thun MJ, Calle EE (2006) Adult weight gain and histopathologic characteristics of breast cancer among postmenopausal women. Cancer 1107:12–21

    Article  Google Scholar 

  25. Schmid P, Possinger K, Bohm R, Chaudri V, Verbeek V, Grosse Y, Luftner D, Petrides P, Sezer O, Wischnewsky M (2000) Body mass index as predictive parameter for response and time to progression (TTP) in advanced breast cancer patients treated with letrozole or megestrol acetate. Proc Am Soc Clin Oncol 19:2000 (abstr 398)

    Google Scholar 

  26. Michaud LB, Buzdar AU, Rubin S, Steinberg M, Yin H, Aaronson L, Nabholtz JM (2002) The efficacy of anastrozole is not dependent upon body mass index (BMI) in postmenopausal women with advanced breast cancer (BC). Proc Am Soc Clin Oncol 21:2002 (abstr 219)

    Google Scholar 

Download references

Acknowledgments

The study was supported by grants of the German Ministry of Education and Research (BMBF).

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Mathematics and Computer Science, University Bremen, Universitätsallee/GW1, 28359, Bremen, Germany

    R. Wolters & M. Wischnewsky

  2. Department of Gynaecology and Obstetrics, University Hospital Ulm, Ulm, Germany

    L. Schwentner, R. Kreienberg & A. Wöckel

  3. Department of Oncology and Haematology, Charité Universitätsmedizin Berlin, Berlin, Germany

    A. Regierer

Authors
  1. R. Wolters
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L. Schwentner
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Regierer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Wischnewsky
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R. Kreienberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A. Wöckel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R. Wolters.

Additional information

The authors R. Wolters and L. Schwentner contributed equally to this manuscript.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wolters, R., Schwentner, L., Regierer, A. et al. Endocrine therapy in obese patients with primary breast cancer: another piece of evidence in an unfinished puzzle. Breast Cancer Res Treat 131, 925–931 (2012). https://doi.org/10.1007/s10549-011-1874-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-011-1874-7

Keywords

Search

Navigation